These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9784793)

  • 1. Abciximab vials as multidose containers.
    Yee WP; Norton LL
    Am J Health Syst Pharm; 1998 Oct; 55(19):2026-7. PubMed ID: 9784793
    [No Abstract]   [Full Text] [Related]  

  • 2. What accounts for the higher clinical efficacy of intracoronary abciximab?
    De Rosa S; Caiazzo G; Torella D; Indolfi C
    Int J Cardiol; 2013 Oct; 168(4):4410. PubMed ID: 23711455
    [No Abstract]   [Full Text] [Related]  

  • 3. Intracoronary abciximab and local anti-inflammatory effects.
    Dominguez-Rodriguez A; Avanzas P; Abreu-Gonzalez P
    Int J Cardiol; 2013 Oct; 168(3):2872. PubMed ID: 23611746
    [No Abstract]   [Full Text] [Related]  

  • 4. [The value of Abciximab in stent implantation clearly proven].
    Z Kardiol; 1999 Jun; 88(6 Suppl):1-4. PubMed ID: 10434386
    [No Abstract]   [Full Text] [Related]  

  • 5. Seeing is believing.
    White CJ
    Cathet Cardiovasc Diagn; 1997 Oct; 42(2):185-6. PubMed ID: 9328704
    [No Abstract]   [Full Text] [Related]  

  • 6. AIDA STEMI: no benefit for intracoronary abciximab.
    Bertrand OF; Jolly S
    Lancet; 2012 Mar; 379(9819):875-877. PubMed ID: 22357108
    [No Abstract]   [Full Text] [Related]  

  • 7. Mortality in intracoronary versus intravenous abciximab.
    Gupta A; Sharma YP
    Lancet; 2012 Jul; 380(9836):25-6; author reply 26. PubMed ID: 22770452
    [No Abstract]   [Full Text] [Related]  

  • 8. Mortality in intracoronary versus intravenous abciximab.
    Iddriss A
    Lancet; 2012 Jul; 380(9836):25; author reply 26. PubMed ID: 22770453
    [No Abstract]   [Full Text] [Related]  

  • 9. Abciximab vs thrombectomy for reperfusion in myocardial infarction.
    Kikkert WJ; Henriques JP
    JAMA; 2012 Aug; 308(6):565-6; author reply 566-7. PubMed ID: 22871862
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy.
    Reddy MS; Carmody TJ; Kereiakes DJ
    Catheter Cardiovasc Interv; 2001 Apr; 52(4):486-8. PubMed ID: 11285605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abciximab during percutaneous coronary intervention for ST-segment elevation myocardial infarction: intracoronary, intravenous, or not at all?
    Bittl JA
    J Am Coll Cardiol; 2013 Apr; 61(13):1455-7. PubMed ID: 23466079
    [No Abstract]   [Full Text] [Related]  

  • 12. Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?
    Zimarino M; Radico F; Kristensen SD; De Caterina R
    Vascul Pharmacol; 2015 Oct; 73():8-10. PubMed ID: 26254107
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of ticlopidine after stent placement.
    Henry P; Beverelli F
    Circulation; 2000 Jan; 101(3):E46-7. PubMed ID: 10645941
    [No Abstract]   [Full Text] [Related]  

  • 14. Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial.
    Desch S; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Pauschinger M; Kerber S; Kleinertz K; de Waha S; Eitel I; Schuler G; Thiele H
    J Am Coll Cardiol; 2013 Sep; 62(13):1214-5. PubMed ID: 23850911
    [No Abstract]   [Full Text] [Related]  

  • 15. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
    Kleiman NS; Grazeiadei N; Maresh K; Taylor RJ; Frederick B; Lance ET; Effron MB; Jordan RE; Mascelli MA
    Am Heart J; 2000 Sep; 140(3):492-501. PubMed ID: 10966553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of intravenous abciximab as adjunctive therapy for carotid angioplasty and stent placement.
    Arab D; Yahia AM; Qureshi AI
    Int J Cardiovasc Intervent; 2003; 5(2):61-6. PubMed ID: 12745860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment with abciximab for consecutive bilateral middle cerebral artery occlusion.
    Puetz V; Weise M; von Kummer R; Gahn G
    Cerebrovasc Dis; 2006; 21(5-6):419-21. PubMed ID: 16549911
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe thrombocytopenia after an infusion of abciximab.
    Rubio A; González C; Majado MJ; Salido E; García-Candel F; González-Carrillo J
    Haematologica; 2001 Mar; 86(3):E05. PubMed ID: 11255292
    [No Abstract]   [Full Text] [Related]  

  • 19. Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.
    Patel K; Hursting MJ
    Am J Health Syst Pharm; 2005 Jul; 62(13):1381-4. PubMed ID: 15972381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosis.
    Giupponi L; Cantoni S; Morici N; Sacco A; Giannattasio C; Klugmann S; Savonitto S
    Platelets; 2015; 26(5):498-500. PubMed ID: 24678647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.